The effect of citalopram as an adjunctive therapy with olanzapine or aripiprazole on the improvement of negative symptoms in patients with chronic schizophrenia in placebo - randomized clinical trial

Alborz University of Medical Science0 个研究点目标入组 160 人开始时间: 待定最近更新: 2023年5月1日

适应症

试验速览

暂无简介。

•Patients who, based on criteria, have been diagnosed with schizophrenia and are receiving treatment by a psychiatrist in a psychiatric ward up to 3 years after diagnosis.
•The minimum PANSS score should be 60 in. This score requires a minimum of 20 on the negative symptom subscale and a BPRS score of 41.
•The age range of participants is between 18 and 50.

•The tendency and decision towards suicide in the Hamilton test.
•The tendency and decision towards suicide in the Hamilton test.
•Individuals with a score greater than 14 based on the 17-item Hamilton Depression Rating Scale (HDRS), or meeting major depression criteria, or having a score of above 4 on all but the depression item of the PANAS.
•Patients diagnosed with any type of non-schizophrenic mental disorder, especially bipolar disorder, schizoaffective disorder, and individuals with major depressive disorders that have been identified by a psychiatric interview.
•In addition, patients who have received electroconvulsive therapy (ECT) in the past 2 weeks are not eligible to participate in this study. Any serious or neurological medical condition, pregnancy or lactation, pregnant women without contraception, patients with Class IV and III heart failure, drug or insulin-dependent diabetes, liver disease, or congestive heart failure are not eligible for the study.

发起方

Alborz University of Medical Science